Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by dacha8881on Sep 29, 2009 8:24am

539 Views

Post# 16346238

ready for some good news!

Good things happening...

Sep 28/09	Sep 28/09	Johann, Peter	Direct Ownership	Common Shares	10 - Acquisition in the public market	4,300	$2.650
Sep 28/09	Sep 28/09	Johann, Peter	Direct Ownership	Common Shares	10 - Acquisition in the public market	700	$2.630
Sep 28/09	Apr 15/09	Johann, Peter	Direct Ownership	Common Shares	00 - Opening Balance-Initial SEDI Report
Sep 17/09	Sep 15/09	Cochrane, William Arthur	Indirect Ownership	Common Shares	10 - Acquisition in the public market	4,000	$2.290
Sep 17/09	Sep 16/09	Thompson, Stella Margery	Direct Ownership	Common Shares	10 - Acquisition in the public market	4,000	$2.262